Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
|
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [31] Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
    Maillet, Denis
    Martel-Lafay, Isabelle
    Arpin, Dominique
    Perol, Maurice
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : E30 - E31
  • [32] GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
    Zeng, Liang
    Yang, Nong
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E114 - E116
  • [33] High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Xu, Yuyin
    Chang, Heng
    Wu, Lijing
    Zhang, Xin
    Zhang, Ling
    Zhang, Jing
    Li, Yuan
    Shen, Lei
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 117
  • [34] Crizotinib for ALK rearrangement in non small cell lung cancer
    Merrick, S. A.
    Hunter, S.
    Dalby, M.
    Neat, M.
    McMunagle, E.
    Montes, A.
    Lal, R.
    Ghosh, S.
    LUNG CANCER, 2017, 103 : S29 - S30
  • [35] CLINICAL AND PROGNOSTIC IMPLICATION OF ALK AND ROS1 REARRANGEMENT IN NEVER SMOKER WITH SURGICALLY RESECTED LUNG ADENOCARCINOMA
    Kim, Hye Ryun
    Kim, Min Hwan
    Lim, Sun-Min
    Kim, Eun Young
    Park, Ji Soo
    Kim, Joo Hang
    Shim, Hyo Sup
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1220 - S1220
  • [36] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
    Ou, Sai-hong I.
    Bang, Y-j
    Camidge, D. R.
    Engelman, J. A.
    Clark, J. W.
    Tye, L.
    Wilner, Keith
    Stephenson, P.
    Chung, D. H.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [37] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Ju, Lixia
    Han, Mingquan
    Su, Jinmei
    Wu, Chunyan
    Dong, Zhengwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 561 - 564
  • [38] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Lixia Ju
    Mingquan Han
    Jinmei Su
    Chunyan Wu
    Zhengwei Dong
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 561 - 564
  • [39] Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib
    Chen, Yao
    Zhang, Xiaochen
    Jiang, Qi
    Wang, Bo
    Wang, Yina
    Yan Junrong
    LUNG CANCER, 2020, 146 : 370 - 372
  • [40] Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
    Clark, Jeffrey W.
    Camidge, D. Ross
    Kwak, Eunice L.
    Maki, Robert G.
    Shapiro, Geoffrey I.
    Chen, Isan
    Tan, Weiwei
    Randolph, Sophia
    Christensen, James G.
    Ozeck, Mark
    Tang, Yiyun
    Wilner, Keith D.
    Salgia, Ravi
    FUTURE ONCOLOGY, 2020, 16 (01) : 4289 - 4301
12345